NeoVax is a vaccine of up to 20 predicted individual tumor neoantigens inducing multifunctional CD4+ and CD8+ T cells to target 60% and 16% of new neoantigens observed in patients with cancers, respectively. Here, CD8A is linked to neoplasm.